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Abstract
Abnormal generation of neurotoxic amyloid-b peptide (Ab) 42/43
species due to mutations in the catalytic presenilin 1 (PS1) subunit
of c-secretase is the major cause of familial Alzheimer’s disease
(FAD). Deeper mechanistic insight on the generation of Ab43 is still
lacking, and it is unclear whether c-secretase modulators (GSMs)
can reduce the levels of this Ab species. By comparing several types
of Ab43-generating FAD mutants, we observe that very high levels
of Ab43 are often produced when presenilin function is severely
impaired. Altered interactions of C99, the precursor of Ab, are
found for all mutants and are independent of their particular
effect on Ab production. Furthermore, unlike previously described
GSMs, the novel compound RO7019009 can effectively lower Ab43
production of all mutants. Finally, substrate-binding competition
experiments suggest that RO7019009 acts mechanistically after
initial C99 binding. We conclude that altered C99 interactions are
a common feature of diverse types of PS1 FAD mutants and that
also patients with Ab43-generating FAD mutations could in princi-
ple be treated by GSMs.
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Introduction
Accumulation and deposition of amyloid-b peptide (Ab) species is a
major pathological hallmark of Alzheimer’s disease (AD) [1]. The
various Ab species, 37–43 amino acids in length, are generated from
the C99 fragment of the amyloid precursor protein (APP) by
presenilins 1 and 2 (PS1 and PS2), the catalytic subunits of the
intramembrane-cleaving protease c-secretase [2]. Following an initial
cleavage of the C99 transmembrane domain at the e-site, which
releases the APP intracellular domain (AICD) and gives rise to Ab49
or Ab48, further stepwise carboxy-terminal cleavages occur [2]. Ab49
is sequentially cleaved in a major product line to Ab46, Ab43, and
Ab40, the main Ab species, as well as small amounts of Ab37 (Ab40
product line), while Ab48 undergoes sequential cleavages in an alter-
native product line to Ab45, Ab42, and Ab38 (Ab42 product line) [3].
The longer Ab42 and Ab43 species are highly aggregation-prone and
neurotoxic and considered as the primary trigger of the disease [4].
Since lowering of Ab should be protective against AD pathogenesis,
c-secretase is a target for AD therapy. Small molecules targeting the
enzyme that hold great potential to be beneficial in AD are c-secretase
modulators (GSMs) [5]. GSMs alter the cleavage of C99 toward the
production of non-toxic shorter Ab species [6] and maintain the
cleavage of physiologically important c-secretase substrates [7,8].
These compounds would therefore offer a preferred treatment strat-
egy over a broad inhibition of substrate cleavage, which is considered
a main reason among others, such as pseudo-inhibition [9], for the
failure of c-secretase inhibitors in clinical trials [10].
Mutations in PS1 represent the major cause of early-onset famil-
ial AD (FAD). They lead to the generation of abnormal relative
amounts of the longer Ab forms as a result of a reduced carboxy-
terminal processivity [11,12]. In support of their pathogenicity,
changes in the ratios of Ab42 to Ab40 correlate with the clinical age
of onset of the particular PS1 FAD mutant [13]. While it has been
well established that Ab42/Ab40 ratios are increased for PS1 and
PS2 FAD mutants [14,15], in a few cases such as the PS1 R278I or
PS1 L435F mutants increased levels of Ab43 rather than Ab42 are
observed [16–18]. For these mutants, the processivity changes
appear also to be associated with a stronger loss of function in the e-
site cleavage of C99 [16,17,19]. However, since deficiencies in the
initial e-site cleavage are largely compensated by the unaffected wt
PS1 and PS2 alleles in human FAD brain, while pathogenic Ab ratios
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persist [20], it is unlikely that FAD mutant c-secretases show an
impact on signaling functions.
PS1 and PS2 normally undergo presenilin endoproteolysis [21] in
which they are autoproteolytically cleaved into N- and C-terminal
fragments (NTF, CTF) [2]; however, in a few FAD mutants, this step
is blocked or impaired. This is also and prominently seen for the
PS1 R278I and PS1 L435F mutants [16–19] indicating that their
strong deficiency in presenilin endoproteolysis may contribute to
their loss in processivity thereby resulting in the formation of longer
Ab43 species.
In an attempt to better understand the molecular characteristics
and disease mechanisms of clinical presenilin mutants, we recently
observed that two Ab42-increasing FAD mutants show altered inter-
action/positioning of the C99 cleavage site domain within the active
site region of c-secretase [22]. In the current study, we wanted to
examine whether this may also be a property for the Ab43-increasing
mutants, possibly even more severe, or whether their altered cleav-
age activities may be unrelated to substrate positioning changes.
Since Ab43 is considered to be the major pathogenic species for these
FAD cases, we also investigated whether a GSM could lower the
aberrant Ab43 levels generated by these mutants and whether such a
compound would have effects on the interaction with C99.
We found significant changes in the C99 interactions with c-
secretase around the e-sites for the Ab43-generating PS1 FAD
mutants, showing that altered interactions of this region of C99 with
PS1 can also be linked to the aberrant generation of this long Ab
variant. In contrast to other well-characterized GSMs, RO7019009, a
novel and potent GSM, could lower Ab43 for all mutants analyzed.
Although RO7019009 could affect to some extent the interaction of
C99 with WT PS1 and some of the mutants, there was no clear
correlation between these changes and the capability of the GSM to
lower Ab42/43. We conclude that Ab43 can be targeted by GSMs
and that altered substrate interactions are a common characteristic
of presenilin FAD mutants associated with the generation of patho-
genic Ab species.
Results
Altered substrate positioning by Ab43-generating PS1
FAD mutants
To investigate whether altered substrate interactions are a molecular
characteristic of Ab43-generating PS1 FAD mutants, we generated
HEK293 cells stably overexpressing Swedish (sw) mutant APP
(HEK293/sw) in combination with presenilin mutants that produce
different amounts of Ab43. In the first set of mutants, we included
strong loss-of-function FAD mutants, which were also deficient in
presenilin endoproteolysis. This set contained the previously charac-
terized PS1 R278I and L435F mutants as well as the PS1 V261F
mutant, which we identified as additional extreme Ab43-generating
loss-of-function mutant by candidate screening. As a control, we
included the uncleavable PS1 M292D mutant, which is known to
support APP processing despite being deficient in presenilin endopro-
teolysis [23]. In a second set, we investigated normally endoproteol-
ysed PS1 mutants. This set included the PS1 L166P and Y256S FAD
mutants, which generate high amounts of Ab42 as the prevailing
pathogenic Ab species besides Ab43 [24] as well as the synthetic
G382A mutant, which generates higher amounts of Ab43 than Ab42
[25] and is therefore predicted to cause FAD if it occurred in humans.
As shown in Fig 1A and B, the mutants of both categories showed the
expected behavior in presenilin endoproteolysis and APP processing
as judged from their respective effects on PS1 NTF and CTF as well as
total secreted Ab levels. Tris–Bicine urea SDS–PAGE, mass spectrom-
etry, and ELISA documented the expected profiles of the individual
Ab species generated by the mutants and identified very high relative
amounts of Ab43 for the previously uncharacterized PS1 V261F
mutant (Fig 1B and C and Appendix Fig S1).
Next, we asked whether the mutants would show altered
substrate interactions with c-secretase as recently shown for the PS1
A246E and L166P FAD mutants [22]. To this end, we used our previ-
ously established photocrosslinking approach by which substrate
binding to CHAPSO-solubilized c-secretase is assessed with recombi-
nant C99 variants engineered to carry the photocrosslinkable non-
natural amino acid p-benzoylphenylalanine (Bpa) at any residue of
interest [22]. By probing the interactions of the most prominent
crosslinking residues that were determined in the previous study for
C99 in the major substrate-binding site of c-secretase, the PS1 NTF,
we observed similar interaction profiles for PS1 WT and the
uncleaved M292D mutant. The major contact point of C99 was at
V44, and additional interactions at the e-sites T48 and L49 were
observed. Being expressed as an uncleaved presenilin, the M292D
variant also showed crosslinking at L52, which interacts with PS1
WT primarily in the PS1 CTF [22] (Fig 2A). The FAD mutants were
generally interacting with the substrate differently from the WT and
M292D controls (Fig 2A). V44 remained the major interaction site of
C99 for all mutants. Some of them, however, displayed reduced V44
crosslinking as prominently seen for the R278I mutant (Fig 2A). The
strong loss-of-function mutants showed similar alterations at the
T48/L49 sites (Fig 2A) as reflected by increased ratios of T48/L49
crosslinking efficiencies (Fig 2B) compared to the corresponding
M292D control. In addition, they showed altered interactions with
C99 residues C-terminal of the e-cleavage sites (Fig 2A). Particularly,
the V261F and R278I mutants displayed increased crosslinking at
K54 relative to the major interaction site V44 (Fig 2C). Consistent
with our previous results [22], the L166P mutant showed shifts in
substrate crosslinking at the T48 and L49 sites compared to WT
(Fig 2A and B). This was also seen for the Y256S mutant, although
in opposite direction (Fig 2B). The PS1 G382A mutant showed less
pronounced alterations at these sites (Fig 2A and B) but a strong
increase in crosslinking at L52 (Fig 2A). Taken together, the mutants
showed distinct and individual changes of C99 crosslinking as
compared to the respective WT and M292D controls. We conclude
that altered substrate positioning is also observed for FAD mutants
that generate Ab43.
The novel GSM RO7019009 effectively lowers Ab43 of all Ab43-
generating mutants investigated
Previous studies showed that aberrant Ab42 generation could be
modulated with potent second-generation GSMs for many FAD
mutants [26–28], with only a few exceptions such as the PS1
L166P mutant [26,27]. To analyze whether Ab43 could also be
lowered by such GSMs, two compounds of different structural
classes were tested on the prototypic uncleaved PS1 R278I mutant
and on the normally endoproteolysed PS1 L166P mutant. GSM-1
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[24] (Fig EV1A) was used as a representative of the acidic GSMs
and RO-02 [29] (Fig EV1B) as one of the non-acidic GSMs with a
bridged aromatic scaffold [5]. As shown in Fig EV1C and D, both
modulators weakly reduced Ab43 production for R278I and only
poorly, if at all, for L166P. Ab42 levels remained unaffected by
both GSM-1 and RO-02 treatment. We thus tested the novel
compound RO7019009 (Figs 3A and EV2), which shows favorable
CNS drug-like properties [30] and has excellent metabolic stability
(Table EV1). RO7019009 efficiently reduced the levels of Ab42 and
Ab40 secreted by HEK293/sw cells in a dose-dependent manner
while concomitantly increasing that of Ab38 (Fig 3B). An IC50 of
14 nM for the inhibition of Ab42 in these cells characterized
RO7019009 as one of the most potent GSMs (Fig 3C and D). The
IC50 (Ab42) values were even lower for brain-derived human
CA
B
Figure 1. Expression, endoproteolysis, and APP processing of Ab43-generating PS1 FAD mutants.
A Immunoblot analysis of presenilin expression and endoproteolysis in cell lysates of untransfected HEK293/sw cells endogenously expressing presenilin and single-cell
clones overexpressing PS1 WT or the indicated PS1 mutants.
B Immunoblot analysis of total Ab secretion and the production of different Ab species (shown in low and high immunoblot exposures) in conditioned media of cell
lines described in (A).
C Mass spectrometry analysis of Ab species immunoprecipitated from conditioned media of cell lines described in (A).
Source data are available online for this figure.
▸Figure 2. Ab43-generating PS1 FAD mutants show altered C99 interactions.A Immunoblot analysis of C99–PS1 NTF or full-length (FL) crosslinks (CL) of the indicated mutants. Samples that were not UV-irradiated were loaded to control for
specificity.
B Changes in the ratio of crosslink efficiencies at positions T48 and L49 compared to corresponding controls (n = 4–5 biological replicates).
C Changes in the ratio of crosslink efficiencies at positions K54 and V44 compared to corresponding controls (n = 4–5 biological replicates).
Data information: Data in (B) and (C) are presented as mean  SD.
Source data are available online for this figure.
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neuroglioma H4 (IC50 (Ab42) = 5 nM) or mouse neuroblastoma
N2a (IC50 (Ab42) = 2 nM) cell lines overexpressing swAPP (H4/
sw, N2a/sw) (Fig 3D). Importantly, the signaling cleavage of
Notch1 was spared by the compound (IC50 (Notch1) > 10 lM) as
assessed in a HEK293 cell-based luciferase reporter assay (Fig 3D).
As expected for a GSM, RO7019009 did not reduce total Ab levels
(Fig 3E). However, the inhibition of both Ab40 and Ab42 genera-
tion (Fig 3B and C) indicated that the c-secretase activity profile
was modulated toward an enhanced processivity in both Ab
product lines. This was confirmed by Tris–Bicine urea SDS–PAGE
analysis of the Ab species which revealed an increased generation
of both Ab37 and Ab38 with the reduction of Ab40 and Ab42
(Fig 3F). The rather strong reduction of Ab40 with the concomi-
tant increase in generation of Ab37 indicated that RO7019009
might be potent in lowering Ab43, which is generated in the Ab40
product line.
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Figure 3. Characterization of RO7019009.
A Structure of RO7019009.
B ELISA of Ab species in conditioned medium of HEK293/sw cells treated with RO7019009 or vehicle (DMSO). Ab levels are shown relative to DMSO vehicle control
(n = 4 biological replicates).
C Dose–response curve of RO7019009 in HEK293/sw cells measured using the MSD sandwich immunoassay (n = 3 biological replicates).
D Dose–response curves for inhibition of Ab42 generation and Notch cleavage by RO7019009 in different cell lines. Comparison of in vitro potencies for Ab42 inhibition
in HEK293/sw cells, IC50 = 14 nM (n = 3) (as in (C)) with those in H4/sw cells, IC50 = 5 nM (n = 7) and N2a/sw cells, IC50 = 2 nM (n = 6) together with that of Notch
cleavage inhibition in a HEK293-based Notch1 luciferase reporter cell line, IC50 > 10 µM (n = 2) (all n numbers represent biological replicates).
E Left panel: Immunoblot analysis of total Ab in conditioned media of HEK293/sw cells treated with RO7019009 or vehicle (DMSO). Total APPs levels were analyzed to
control for normal APP secretion and equal sample loading. Right panel: Quantification of relative Ab amounts in (E) (n = 2 biological replicates).
F Immunoblot analysis of Ab species in conditioned media of RO7019009-treated HEK293/sw cells after separation by Tris–Bicine urea SDS–PAGE; synthetic Ab peptides
were loaded as size markers.
Data information: Data in (B–F) are presented as mean  SD.
Source data are available online for this figure.
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We next tested the response of the mutants to RO7019009 over a
concentration range from 50 to 500 nM. As judged from increased
Ab38 levels, measurements of Ab species by ELISA showed that
RO7019009 could enhance the processivity of c-secretase in all
mutants (Fig 4A). Furthermore, specific detection and quantitation of
Ab43 by ELISA showed that RO7019009 reduced the generation of
Ab43 for all mutants including the extreme V261F and R278I mutants,
which generated the highest amounts of Ab43 (Fig 4B). Ab42 levels
could also be efficiently lowered by RO7019009 for several mutants.
However, some mutants showed the tendency of a strongly attenuated
Ab42-lowering response (Fig 4C). In particular, the PS1 V261F and
R278I mutants were partially resistant to RO7019009. Likewise, Ab42
levels remained largely unaffected for the L166P mutant (Fig 4C),
recapitulating the effect of other potent GSMs on this FAD mutant
[24,26,27]. Additional experiments at the 500 nM RO7019009 dose
followed by ELISA of Ab42 levels confirmed a small, yet significant,
reproducible reduction of this species for the less responsive V261F,
R278I, and L166P mutants (Fig EV3). These data suggest that the
processivity of the V261F, R278I, and L166P mutants can be enhanced
by RO7019009 more easily in the Ab40 product line than in the Ab42
product line for which much higher GSM concentrations are required.
The fact that Ab43 can be directly processed to Ab38 [31] might
explain the increased levels of Ab38 of these refractory mutants at
lower concentrations of RO7019009.
Mass spectrometry analysis confirmed the reduction of Ab43 and
Ab42 levels upon treatment with 500 nM RO7019009, including the
Ab42 reduction in the V261F, R278I, and L166P mutants, and also
showed a nearly complete reduction of Ab40 for all mutants (Fig 5).
As for the parental HEK293/sw cells (Fig 3F), RO7019009-treated PS1
WT overexpressing cells generated high amounts of both Ab37 and
Ab38 (Fig 5). This GSM response was also observed for the uncleaved
PS1 M292D control and the PS1 V261F and L435F mutants, although
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Figure 4. Modulation of PS1 FAD mutants with RO7019009.
A–C ELISA of Ab species in conditioned media of HEK293/sw cells overexpressing WT or mutant PS1 treated with RO7019009 or vehicle (DMSO) showing the secretion of
Ab38 (A), Ab43 (B), and Ab42 (C) compared to total Ab (Ab38 + Ab40 + Ab42 + Ab43) (n = 5 biological replicates). Note that in some experiments, Ab38 generation
was below the detection limit for some mutants. Data are presented as mean  SD.
Source data are available online for this figure.
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the two latter mutants generated less Ab37 than Ab38. Interestingly,
the other mutants generated mostly or nearly exclusively Ab38 when
treated with RO7019009, although longer species of both product lines
were reduced. An enhanced direct cleavage of Ab43 to Ab38 effected
by the GSM thereby skipping the production of Ab40 and Ab37 could
underlie this observation. Tris–Bicine urea SDS–PAGE analysis
provided further independent proof of these findings (Fig EV4).
Differential effects on substrate crosslinking in the presence
of RO7019009
Changing the interaction of C99 with PS1 could be a potential mode
of action of GSMs. To analyze this, C99 V44Bpa was crosslinked to
PS1 in the presence of increasing concentrations of RO7019009. As
shown in Fig 6A and B, crosslinking of the substrate to WT PS1
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Figure 5. Modulation of Ab profiles of PS1 FAD mutants by RO7019009.
Mass spectrometry analysis of Ab species immunoprecipitated from conditioned media of HEK293/sw cells overexpressing WT or mutant PS1 treated with 500 nM
RO7019009 or vehicle (DMSO).
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NTF was reduced in the presence of RO7019009 in a dose-dependent
manner. Although this was also the case for several mutants, the
effect of the treatment was distinct for every mutant and if clearly
visible, only at very high GSM concentrations (Fig 6A–D). Notably,
the PS1 Y256S and R278I mutants displayed an unchanged
crosslinking. To assess whether these high concentrations of
RO7019009 are tolerated by the mutants in the substrate-binding
assay, we analyzed their activities to cleave C99 under similar
conditions in cell-free cleavage assays. As seen from the increased
Ab37/38 levels, the response to the GSM was maintained by all
mutants (Fig EV5A). Moreover, the GSM had little if any inhibiting
effect on the initial e-site cleavages. Even in the presence of 2.5 lM
RO7019009, total AICD generation was not or only marginally
reduced (Fig EV5B and C). This was not only true for the Y256S and
R278I mutants that displayed unchanged crosslinking upon GSM
treatment, but also for those mutants that displayed reduced
substrate crosslinking. Since reduced overall substrate binding
should result in decreased total activity, the unchanged total activity
in the presence of the GSM indicates normal overall C99 binding.
Thus, the reduced V44 crosslinking levels likely reflect conforma-
tional changes of the C99–PS1 substrate–enzyme complex causing
altered local substrate interactions. The reduced crosslinking of C99
to the WT may be correlated with the positive response to the GSM
in the cell-based assay (Fig 4). However, since C99 crosslinking was
not reduced in case of the well responsive Y256S mutant, these data
argue against a direct link between reduced C99 crosslinking and
GSM-mediated changes in Ab generation.
Discussion
Since Ab43 is increasingly recognized as another toxic species
besides Ab42 in AD pathogenesis, we sought deeper mechanistic
insights into the generation of Ab43 by the PS1 FAD mutants that
produce abnormal amounts of it. In addition, we wanted to know
whether Ab43 production by such mutants could be inhibited by
GSMs. In profiling and comparing different types of Ab43-generating
PS1 mutants, we observed that mutants that showed a severe loss-
of-function phenotype manifesting with strongly reduced total c-
secretase activity and impaired presenilin endoproteolysis produced
Ab43 as prevailing pathogenic Ab species. This principle was
supported by the V261F mutant that was included in our study as a
candidate for the generation of Ab43 based on a previous report that
it nearly fully inhibits Ab generation [32]. On the other hand, the
mutants that were cleaved into PS1 NTF and CTF produced lower
relative amounts of Ab43. For these mutants, the levels of Ab43
could still be higher (PS1 G382A) or lower (PS1 L166P and Y256S)
than that of Ab42. Of note, the combination of extremely high
amounts of Ab42 with an additional production of Ab43 in the two
latter FAD cases might possibly be causative for or contribute to the
very early disease onset in these patients [33,34]. Taken together,
our study suggests that the effects on the generation of Ab43 are
rather dramatic when presenilin endoproteolysis is also impaired. A
correlation between presenilin endoproteolysis deficiency and
increased generation of Ab43 may have been indicated in an earlier
study for several other mutants besides PS1 R278I although the
ELISA used at that time could not distinguish Ab42 from Ab43 [35].
However, one should note that such a correlation might not always
exist as evident from the poorly endoproteolysed PS1 C410Y
mutant, which produces ~5-fold more Ab42 than Ab43 [18].
Since FAD mutants that generate very high amounts of Ab43 are
often associated with a strong loss of presenilin function, we asked
whether such mutants could have even more severe and/or
distinctly changed interactions within and around the cleavage
domain of C99 compared to mutants that preferentially generate
Ab42. First of all, we found that also the Ab43-generating mutants
clearly changed their interaction with C99, possibly reflecting an
altered conformation of the substrate–enzyme complex around the
C99 cleavage site region. Thus, altered interactions of C99 with c-
secretase are a general feature of presenilin FAD mutants of various
biochemical phenotypes. Mutants that generate abnormal amounts
of either Ab42 and/or Ab43 interact with C99 differently from WT
and independently of whether they undergo presenilin endoproteol-
ysis or not. However, the relative extents of the alterations of C99
crosslinking at the individual positions analyzed were different for
the individual mutants. Interestingly, as observed previously for the
PS1 A246E and L166P mutants [22], altered crosslinking at T48 and
L49, i.e., at the initial substrate cleavage sites of C99, was also
observed for the Ab43-generating mutants suggesting that these
could be a common pattern of FAD mutants. In addition, a rather
unique crosslinking change of L52 was seen for the G382A mutant
and increased crosslinking at K54 even more C-terminal to the e-
sites was found for the poorly endoproteolysed PS1 V261F and
R278I mutants, which produced the highest levels of Ab43. The
changes in the substrate interactions caused by the FAD mutants
can be rationalized using the recently obtained structure of the APP
C83 substrate in complex with the PS1 c-secretase complex [36].
The FAD mutations and the substrate contact residues analyzed
here are all proximal to the active site region (Appendix Fig S2).
The positioning alterations of the C99 cleavage region caused by the
FAD mutants likely contribute to altered e-site cleavages that can
occur for such mutants [11,37] and could also impact on the ensu-
ing Ab substrate–c-secretase interactions. The strengths of these
interactions play a key role throughout the carboxy-terminal
◀ Figure 6. Partial effects of RO7019009 on C99–PS1 crosslink formation.A Immunoblot analysis of C99 V44Bpa crosslinking (CL) to PS1 NTFs (circle) of WT or normally endoproteolysed mutants in the presence of vehicle (DMSO) or
RO7019009.
B Quantitation of crosslink efficiencies of C99 V44Bpa to the WT or mutant NTF in (A).
C Immunoblot analysis of C99 V44Bpa crosslinking to full-length (FL) PS1 (triangle) of endoproteolysis-deficient mutants and the corresponding M292D control in the
presence of vehicle (DMSO) or RO7019009.
D Quantitation of crosslink efficiencies of C99 V44Bpa to the M292 or FAD mutant FL PS1 in (C).
Data information: Data in (B and D) are presented as box plots (line, median; box, 75th–25th percentiles; whiskers, 1.5× interquartile range (IQR); single points represent
outliers (> 1.5× IQR away from box)) (n = 7–11 biological replicates).
Source data are available online for this figure.
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trimming pathway and the generation of the pathogenic longer Ab
species [31,38]. In future studies, it would thus be interesting to
investigate how FAD mutations would alter interactions of the ensu-
ing Ab substrates with c-secretase using Bpa-mediated photoaffinity
mapping.
A major question of this study was whether Ab43 could be
lowered by GSMs, especially when generated in abnormal amounts
by particular PS1 FAD mutants. Previous in vitro studies including
patient-derived neuronal cells showed that Ab42 could be lowered
for many presenilin FAD mutants by potent GSMs [26–28] opening
treatment possibilities, for example, within the Dominantly Inher-
ited Alzheimer Network (DIAN) [39], based on a rational selection
of a GSM effective for a given presenilin FAD mutation. We now
show that Ab43 production can also be inhibited by modulation of
c-secretase activity. We identified RO7019009 as a potent GSM with
CNS drug-like properties, which could lower Ab43 generation in all
investigated mutants. These include the PS1 R278I and PS1 L166P
mutants for which the well-characterized GSMs RO-02 and GSM-1
showed strongly reduced efficacy as compared to PS1 WT.
However, although RO7019009 could efficiently inhibit the genera-
tion of Ab43 in all the mutants, remarkably, for some of the mutants
including the strong Ab43-overproducing PS1 mutants V261F and
R278I, their concomitant Ab42 production could only be inhibited at
higher RO7019009 concentrations and only to small extents. The
same observation was also made for the L166P mutant, but not for
the Y256S mutant, which has a very similar Ab profile as the L166P
mutant. For the PS1 Y256S mutant, production of both Ab42 and
Ab43 could be efficiently inhibited at low RO7019009 concentra-
tions. In addition, generation of the shorter Ab species was differen-
tially affected by RO7019009 in the various mutants. Some mutants
were modulated in a way that increased levels of both Ab37 and
Ab38, while others showed only minor or no generation of Ab37
while still producing high levels of Ab38. These observations
suggest that RO7019009 differentially affects the two product lines
in certain mutants resulting in, e.g., less effective Ab42 reduction or
generation of predominantly Ab38.
GSMs have been shown to reduce the dissociation of Ab42–c-
secretase complexes and increase their stability [31,38]. The result-
ing longer substrate residence time would thereby allow more
efficient carboxy-terminal processing toward shorter Ab species.
Mutational analysis further showed that the activity of GSMs is
affected by K28 and nearby residues of the extracellular TMD border
of C99 [40–42]. As shown very recently, these effects relate func-
tionally to the proximity of K28 to NCT [36,43] and indicate this
contact region with C99 and/or Ab also as part of a GSM binding
site [44].
Since it remained possible that RO7019009 may exert its activity
by affecting the interaction of C99 with c-secretase, we probed the
crosslinking of V44, which represents the position of C99 that shows
the most efficient crosslink in the PS1 NTF [22]. While two mutants
did not change crosslinking in the presence of the GSM, it was
decreased for WT PS1 and most mutants, although to different
extents. Notably, total c-secretase activity was unaffected by the
GSM. Thus, the crosslinking changes induced by RO7019009 seem
to be due to a slightly changed substrate–enzyme complex confor-
mation causing altered local substrate docking rather than
decreased overall substrate binding. However, since clear effects of
allosteric modulation by RO7019009 at this major interaction site of
c-secretase were observed only at very high concentrations of the
GSM, it is probable that these effects are not relevant for the activity
of the GSM. Rather, the interactions with c-secretase could be
changed for long Ab species, which become the ensuing substrates
after C99 has been cleaved [31,38]. Effects on the interactions of
further processed Ab species originating from Ab48/49 with the
protease seem even more likely since GSMs do not change cleavage
of C99 at the e-sites [29,45]. Conformational changes in the prese-
nilin active site region upon GSM binding that have been reported
earlier [46] may therefore affect c-secretase at this level. Thus, the
altered crosslinking efficiencies of C99 observed here could more
likely reflect a broader conformational enzyme change induced by
the GSM, supporting the idea that GSMs rather act on the sequential
carboxy-terminal cleavage of the longer Ab42/43 species.
In conclusion, our study shows that all investigated Ab43-gener-
ating PS1 FAD mutants affect the interaction of the C99 cleavage site
region with c-secretase. Altered C99–c-secretase interactions are
thus a general feature of presenilin FAD mutants reinforcing the
concept that such changes are critically contributing to the mecha-
nism of the pathogenic activity of FAD caused by presenilin muta-
tions. As an important implication for AD therapy approaches, we
conclude that Ab43-generating FAD mutations should in principle
be targetable by c-secretase modulation, which could be beneficial
for such mutation carriers.
Materials and Methods
Antibodies
Antibodies to the PS1 CTF (3027 [47], immunoblot (IB): 1:4,000),
the PS2 CTF (BI.HF5c [23], IB: 1:2,000) as well as antibodies to total
Ab (3552 [48], immunoprecipitation (IP) 1:500 and 2D8 [49], IB
3 lg/ml) have been described previously. Monoclonal antibody 2G7
(IgG2b/k) (IB 3 lg/ml) to the PS1 NTF was raised in C57/BL6 mice
against residues 39–52 (NDRRSLGHPEPLSN) of human PS1. Anti-
bodies N1660 to NCT (Sigma N1660, IB 1:1,000), 22C11 to secreted
soluble APP (Merck Millipore MAB348, IB 1:5,000), 4G8 to Ab
(Covance SIG-39220, IP 1:500–1:2,500), Y188 to the APP C-terminus
(Abcam ab32136, IB 1:4,000), and Penta-His (Qiagen 34460, IB
1:2,000) were obtained from the indicated companies. Species-
specific anti-Ab antibodies to Ab40 (BAP24) and Ab42 (BAP15) were
kindly provided by Manfred Brockhaus (Roche Applied Science) and
SULFO-tagged according to the instructions of the supplier (Meso
Scale Discovery (MSD)). The anti-Ab37 antibody (D2A6H) was
obtained from Cell Signaling (#12467S) and SULFO-tagged as above.
The SULFO-tagged antibody against Ab38 was obtained from MSD.
cDNA constructs
PS1 mutations were introduced into pcDNA3.1/Zeo(+) expression
vector containing the WT PS1 cDNA by site-directed mutagenesis
and verified by sequencing.
Cell lines and cell culture
Single-cell clones of HEK293 cells stably co-expressing swAPP with
WT and mutant PS1 constructs were cultured as described [50]. For
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GSM treatments, the cells were grown to a confluence of 70–80%.
Thereafter, medium was changed to fresh medium containing either
DMSO vehicle control or GSM at the indicated concentration and
the cells were incubated for 16–18 h before Ab analysis of condi-
tioned medium. Single-cell clones of H4 overexpressing swAPP and
HEK293-based Notch1 reporter cell lines were cultured and treated
with GSM as described [51]. Mouse N2a cells stably overexpressing
swAPP were cultured in DMEM (high glucose) supplemented with
10% FCS and 1 mM sodium pyruvate and treated with GSM as
described above.
GSMs
GSM-1 and RO-02 have been described previously [24,29].
RO7019009 was synthesized as depicted in Fig EV2.
Protein analysis
Immunoblot analysis of PS1 and PS2, NCT, full-length APP, C-term-
inal APP fragments, secreted APPs, and Ab was performed as
described [52]. To analyze GSM dose responses and determine IC50
values for Ab42 inhibition, secreted Ab species of HEK293/sw cells
were analyzed by sandwich immunoassay (MSD) using SULFO-
tagged C-terminal specific antibodies to Ab38, Ab40, and Ab42 as
described before [26] or, in case of H4/sw and N2a/sw cells by an
Ab42 AlphaLISA immunoassay kit according to the instructions of
the supplier (PerkinElmer). Notch1 cleavage reporter assay was
carried out as described [51]. GSM-mediated changes of secreted Ab
species in conditioned medium of PS1 WT or mutant expressing
HEK293/sw cells were quantified by ELISA using end-specific C-
terminal antibodies to Ab38, Ab40, Ab42, and Ab43 obtained from
IBL as described previously [16]. Mass spectrometry analysis of
secreted Ab species was performed after immunoprecipitation using
antibody 4G8 as described previously [17]. Individual Ab species
were analyzed by immunoblotting, using Tris–Bicine urea SDS–
PAGE [53]. To improve the separation of longer Ab species (e.g.,
Ab42/43), the separation gel was adjusted to 8% acrylamide and
8 M urea. Ab37 and Ab38 generated in cell-free c-secretase assays
were analyzed by sandwich immunoassay (MSD) as above using
SULFO-tagged species-specific antibodies. AICD generation in these
assays was analyzed by immunoblotting with Penta-His antibody
after sample separation on 10–20% Tris–Tricine gels (Invitrogen).
Protein bands from immunoblots were quantified using the LAS-
4000 image reader (Fujifilm Life Science) and Multi-Gauge V3.0 soft-
ware for analysis.
Substrate photocrosslinking
Bpa-containing C99-based c-secretase substrates were prepared as
described previously [22]. CHAPSO-lysates were prepared from
HEK293/sw cells co-expressing either PS1 WT or PS1 mutants.
Photocrosslinking was performed as described before [22].
Crosslinking of the substrates was analyzed by immunoblotting
using antibodies against the PS1 NTF as described [22]. For
substrate crosslinking experiments in the presence of RO7019009,
the cell lysates were pre-incubated for 30 min on ice with
RO7019009 or DMSO vehicle before the addition of C99 V44Bpa and
subsequent photocrosslinking.
Cell-free c-secretase assay
Membrane fractions were prepared from HEK293/sw cells co-
expressing WT or mutant PS1 as described before [54]. c-secretase
was solubilized from the membrane fractions with 1% CHAPSO and
used for cell-free cleavage assays with recombinant C100-His6 as
substrate as described [17].
Expanded View for this article is available online.
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